SCHEMBL5795280

SCHEMBL5795280

Cc1c(C)c2c(c(C)c1O)CCC(C)(/C=C/c1ccccc1)O2

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
TSHR P16473 1/20 0.50
BCHE P06276 8/20 0.41
ACHE P22303 8/20 0.41
ALOX5 P09917 3/20 0.40
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
GSTP1 P09211 1/20 0.39
TTPA P49638 1/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.39
THRB P10828 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5795281 1.00 PTGS1 (0.50) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL5795283 1.00 PTGS1 (0.50) PTGS1PTGS2CYP1A2CYP3A4TSHR
Hydrochloric Acid SCHEMBL9467589 0.82 PTGS1 (0.43) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL9659381 0.76 CYP3A4 (0.56) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL9659372 0.76 CYP3A4 (0.56) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL13979807 0.76 CYP3A4 (0.60) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL3035038 0.76 CYP3A4 (0.60) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL1286097 0.75 PTGS2 (0.41) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL19895323 0.73 PTGS1 (0.51) PTGS1PTGS2CYP1A2CYP3A4TSHR
SCHEMBL9851129 0.73 MAPT (0.50) PTGS1PTGS2CYP1A2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106014-A1 Methods for treating diabetes ELI LILLY AND COMPANY 2006-05-18 US claimed
WO-2006044556-A2 DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES GALILEO PHARMACEUTICALS, INC. (US) 2006-04-27 WO claimed
US-20060106014-A1 Methods for treating diabetes ELI LILLY AND COMPANY 2006-05-18 US disclosed
WO-2006044556-A2 DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES GALILEO PHARMACEUTICALS, INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106014-A1 Methods for treating diabetes ALOX5, ALOX15, ALOX15B PTGS1 89/4885PTGS2 60/4885CYP1A2 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.